Zika virus (ZIKV) is an arthropod-borne Flavivirus that is spread by infected Aedes mosquitoes. The accurate diagnosis of ZIKV can be complicated due to a variety of factors, including analogous clinical presentation, serological cross-reactivity, or the possibility of co-infection with other co-circulated viruses such as dengue virus and chikungunya virus. Thus, the accurate and rapid diagnosis of vector-borne diseases through validated diagnostic methods is critical in enabling prompt treatment and controlling viral dissemination.
To support research on this virus, ATCC offers ZIKV virus reference materials and solutions for the development of novel vaccines, treatment protocols, and innovative therapeutics. Our portfolio includes in vivo and cell culture–adapted strains, genomic and synthetic nucleic acid preparations, high-titer and heat-inactivated viral preparations, monoclonal antibodies, and host cell lines and reagents.
Explore our Zika virus portfolio
Responding to the Zika crisis
Dr. Randall Kincaid highlights how ATCC supported the Zika epidemic
Explore more resources
Vector-borne diseases
The early detection of vector-borne diseases is imperative in managing microbial dissemination and minimizing the impact of disease on public health. To support the development of these essential tools, ATCC houses a number of products that support research on prevalent vector-borne diseases such as Zika, dengue, chikungunya, malaria, and Lyme disease.
Browse NowZoonotic diseases
The frequency of zoonotic disease transmission has been increasing over time—it is believed that as many as 3 out of every 4 new diseases in humans come from an animal source. As in our response to the COVID-19 pandemic, we will partner with the global research community to acquire, authenticate, maintain, and distribute the clinically relevant pathogens needed to respond to emerging zoonotic diseases.
Explore now
